Mitochondrial Power Determines How Well Immune Cells Fight Cancer
A new Science paper reveals that mitochondrial fitness in dendritic cells controls antitumor immunity — and can be targeted to boost immunotherapy.
Summary
Researchers at St. Jude Children's Research Hospital discovered that conventional type 1 dendritic cells (cDC1s) — immune cells critical for activating cancer-killing T cells — exist in two distinct mitochondrial states inside tumors. Cells with polarized, energized mitochondria were far better at presenting tumor antigens and activating CD8+ T cells than their counterparts with depolarized mitochondria. The protein OPA1, which controls mitochondrial fusion and cristae structure, emerged as the master regulator of this difference. Loss of OPA1 in dendritic cells accelerated tumor growth across multiple cancer models. Crucially, injecting cDC1s with boosted mitochondrial function into tumors significantly improved outcomes, especially when combined with immune checkpoint blockade. These findings point to mitochondrial metabolism as a new lever for cancer immunotherapy.
Detailed Summary
Conventional type 1 dendritic cells (cDC1s) are essential gatekeepers of antitumor immunity: they capture tumor antigens, cross-present them to CD8+ T cells in draining lymph nodes, and help recruit and restimulate cytotoxic T lymphocytes inside tumors. Despite their central role, how the nutrient-depleted, immunosuppressive tumor microenvironment (TME) shapes cDC1 metabolic fitness — and what that means for cancer immunity — has been poorly understood. This study from the Chi lab at St. Jude Children's Research Hospital provides the most comprehensive mechanistic account to date of how mitochondrial biology governs cDC1 antitumor function.
Using tandem mass tag proteomics, the researchers first showed that intratumoral cDC1s from B16-OVA melanoma-bearing mice displayed enrichment of mitochondrial respiration pathways compared to splenic cDC1s, with higher oxygen consumption rates (OCR) and ATP production. This OXPHOS upregulation was conserved across mouse lung adenocarcinoma models and human pan-cancer datasets, establishing it as a broadly relevant feature. Flow cytometry co-staining with TMRM (mitochondrial membrane potential dye) and MitoTracker Green (mitochondrial mass) uncovered two distinct cDC1 subpopulations inside tumors: [TMRM/MG]hi cells with polarized, energized mitochondria and [TMRM/MG]lo cells with depolarized mitochondria. This bimodal distribution was reproducible across B16-OVA melanoma, Lewis lung carcinoma, EO771 breast cancer, and an oncogene-driven hepatocellular carcinoma (HCC) model, and was also detectable in human tumor scRNA-seq datasets.
Functionally, [TMRM/MG]hi cDC1s showed markedly superior capacity to prime OT-I CD8+ T cells and had higher surface expression of MHC-I and MHC-II molecules. Electron microscopy and Seahorse metabolic analysis confirmed that [TMRM/MG]hi cells had elongated mitochondria, denser cristae, greater mitochondrial volume, and higher OCR and ATP production than [TMRM/MG]lo counterparts. Transcriptomic and metabolomic profiling of sorted subpopulations showed that [TMRM/MG]hi cDC1s had enriched antigen cross-presentation gene signatures and upregulation of malate-aspartate shuttle, pyruvate metabolism, and TCA cycle metabolites.
The study pinpointed OPA1 — a dynamin-like GTPase critical for inner mitochondrial membrane fusion, cristae architecture, and electron transport chain (ETC) integrity — as the central regulator. OPA1 was selectively upregulated in intratumoral versus splenic cDC1s, with other fusion/fission proteins (MFN1, MFN2, DRP1) showing no significant change. DC-specific OPA1 knockout mice (Opa1ΔDC, using CD11c-Cre) showed normal DC development and homeostasis but dramatically impaired antitumor responses: B16-OVA, MC38, LLC, and HCC tumors all grew significantly larger in Opa1ΔDC versus wild-type mice. Mechanistically, OPA1 loss reduced ETC complex assembly, dropped NAD+/NADH ratio, and triggered autophagic degradation of MHC-I and antigen via LC3-associated processes. Restoration of NRF1 (nuclear respiratory factor 1) — a transcription factor downstream of OPA1 that supports ETC gene expression — rescued antigen presentation and CD8+ T cell priming in OPA1-deficient cDC1s.
Critically, the study demonstrated therapeutic translational potential. Mitochondrial membrane potential and OPA1-NRF1 signaling both declined in intratumoral cDC1s as tumors progressed. Intratumoral injection of cDC1s with pharmacologically polarized mitochondria (treated with reagents that enhance mitochondrial membrane potential ex vivo) produced robust tumor control in vivo, and the effect was substantially amplified when combined with anti-PD-1 immune checkpoint blockade. These data establish mitochondrial metabolic state as both a mechanistic determinant of cDC1 immunogenicity and a viable therapeutic target for next-generation cancer immunotherapy strategies.
Key Findings
- Intratumoral cDC1s showed higher OCR and ATP production than splenic cDC1s, with mitochondrial respiration being the top enriched pathway by proteomics in B16-OVA tumor-bearing mice
- Two discrete mitochondrial subpopulations — [TMRM/MG]hi (polarized) and [TMRM/MG]lo (depolarized) — were consistently identified across B16-OVA, LLC, EO771, and HCC tumor models, and in human tumor scRNA-seq datasets
- [TMRM/MG]hi cDC1s demonstrated markedly enhanced MHC-I/MHC-II expression and superior OT-I CD8+ T cell priming capacity compared to [TMRM/MG]lo counterparts across all tested tumor models
- DC-specific OPA1 knockout (Opa1ΔDC mice) significantly increased tumor growth and weight in B16-OVA, MC38, LLC, and HCC models, while reducing intratumoral CD8+ T cells and effector-like (TCF1−TIM-3+) CD8+ T cell numbers
- OPA1 loss triggered autophagic degradation of MHC-I and tumor antigen via disruption of NRF1-driven ETC integrity and reduction of NAD+/NADH ratio, mechanistically explaining impaired antigen presentation
- Mitochondrial membrane potential and OPA1–NRF1 signaling both declined progressively in intratumoral cDC1s during tumor progression, correlating with functional exhaustion
- Intratumoral injection of cDC1s with ex vivo-polarized mitochondria produced significant tumor control that was strongly amplified by combination with anti-PD-1 immune checkpoint blockade
Methodology
The study used multiple syngeneic mouse tumor models (B16-OVA, MC38, LLC, EO771, and oncogene-driven HCC) along with DC-specific conditional knockout mice (CD11c-Cre × Opa1fl/fl). Techniques included tandem mass tag multiplex proteomics, Seahorse metabolic flux analysis, electron microscopy, flow cytometry with TMRM/MitoTracker staining, bulk RNA sequencing, untargeted metabolomics, and confocal imaging with TOM20 for mitochondrial volume. Public mouse and human single-cell RNA-seq datasets were interrogated to validate findings. Statistical analyses included GSEA and principal component analysis; specific p-values are reported in the original figures but were not uniformly extractable from the provided full text excerpt.
Study Limitations
The study relies predominantly on murine tumor models; while human scRNA-seq data supports conservation of the [TMRM/MG]hi/lo subpopulation dichotomy, functional validation in human cDC1s and clinical tumor samples is lacking. The truncated full text excerpt limits extraction of all statistical details, sample sizes per experiment, and any author-declared conflicts of interest. The therapeutic experiments use intratumoral injection of polarized cDC1s, which may not be readily translatable to all tumor types or clinical settings without further optimization of delivery and polarization protocols.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.